201 related articles for article (PubMed ID: 33962088)
1. Structure-based design approach of potential BCL-2 inhibitors for cancer chemotherapy.
Krishna S; Kumar SB; Murthy TPK; Murahari M
Comput Biol Med; 2021 Jul; 134():104455. PubMed ID: 33962088
[TBL] [Abstract][Full Text] [Related]
2. Peptide screening to knockdown Bcl-2's anti-apoptotic activity: implications in cancer treatment.
Raghav PK; Verma YK; Gangenahalli GU
Int J Biol Macromol; 2012 Apr; 50(3):796-814. PubMed ID: 22155216
[TBL] [Abstract][Full Text] [Related]
3. Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides.
Modi V; Sankararamakrishnan R
J Mol Graph Model; 2017 May; 73():115-128. PubMed ID: 28279820
[TBL] [Abstract][Full Text] [Related]
4.
Gowtham HG; Ahmed F; Anandan S; Shivakumara CS; Bilagi A; Pradeep S; Shivamallu C; Shati AA; Alfaifi MY; Elbehairi SEI; Achar RR; Silina E; Stupin V; Murali M; Kollur SP
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838574
[TBL] [Abstract][Full Text] [Related]
5. Ligand-based design approach of potential Bcl-2 inhibitors for cancer chemotherapy.
Arakal NG; Sharma V; Kumar A; Kavya B; Devadath NG; Kumar SB; Murthy KT; Murahari M
Comput Methods Programs Biomed; 2021 Sep; 209():106347. PubMed ID: 34399152
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
[TBL] [Abstract][Full Text] [Related]
7. Deciphering the crucial molecular properties of a series of Benzothiazole Hydrazone inhibitors that targets anti-apoptotic Bcl-xL protein.
Marimuthu P; Balasubramanian PK; Singaravelu K
J Biomol Struct Dyn; 2018 Aug; 36(10):2654-2667. PubMed ID: 28793831
[TBL] [Abstract][Full Text] [Related]
8. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy.
Suvarna V; Singh V; Murahari M
Eur J Pharmacol; 2019 Nov; 862():172655. PubMed ID: 31494078
[TBL] [Abstract][Full Text] [Related]
9. Deciphering the crucial residues involved in heterodimerization of Bak peptide and anti-apoptotic proteins for apoptosis.
Marimuthu P; Singaravelu K
J Biomol Struct Dyn; 2018 May; 36(6):1637-1648. PubMed ID: 28511583
[TBL] [Abstract][Full Text] [Related]
10.
Almansour NM; Allemailem KS; Abd El Aty AA; Ismail EIF; Ibrahim MAA
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677841
[TBL] [Abstract][Full Text] [Related]
11. Proteins of the bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities.
Chan SL; Yu VC
Clin Exp Pharmacol Physiol; 2004 Mar; 31(3):119-28. PubMed ID: 15008953
[TBL] [Abstract][Full Text] [Related]
12. Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents.
Balakumar C; Ramesh M; Tham CL; Khathi SP; Kozielski F; Srinivasulu C; Hampannavar GA; Sayyad N; Soliman ME; Karpoormath R
J Biomol Struct Dyn; 2018 Nov; 36(14):3687-3704. PubMed ID: 29064326
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel Plasmodium falciparum PI4KB inhibitors as potential anti-malarial drugs: Homology modeling, molecular docking and molecular dynamics simulations.
Ibrahim MAA; Abdelrahman AHM; Hassan AMA
Comput Biol Chem; 2019 Jun; 80():79-89. PubMed ID: 30928871
[TBL] [Abstract][Full Text] [Related]
14. Relationship between helix stability and binding affinities: molecular dynamics simulations of Bfl-1/A1-binding pro-apoptotic BH3 peptide helices in explicit solvent.
Modi V; Lama D; Sankararamakrishnan R
J Biomol Struct Dyn; 2013; 31(1):65-77. PubMed ID: 22803956
[TBL] [Abstract][Full Text] [Related]
15. Integrating Ligand and Target-Driven Based Virtual Screening Approaches With
Tutumlu G; Dogan B; Avsar T; Orhan MD; Calis S; Durdagi S
Front Chem; 2020; 8():167. PubMed ID: 32328476
[TBL] [Abstract][Full Text] [Related]
16. Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy.
Tomek M; Akiyama T; Dass CR
J Pharm Pharmacol; 2012 Dec; 64(12):1695-702. PubMed ID: 23146031
[TBL] [Abstract][Full Text] [Related]
17. Shedding Light on the Interaction of Human Anti-Apoptotic Bcl-2 Protein with Ligands through Biophysical and in Silico Studies.
Ramos J; Muthukumaran J; Freire F; Paquete-Ferreira J; Otrelo-Cardoso AR; Svergun D; Panjkovich A; Santos-Silva T
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781512
[TBL] [Abstract][Full Text] [Related]
18. Identification of Novel Potential gp120 of HIV-1 Antagonist Using Per-Residue Energy Contribution-Based Pharmacophore modelling.
Berinyuy E; Soliman MES
Interdiscip Sci; 2017 Sep; 9(3):406-418. PubMed ID: 27165479
[TBL] [Abstract][Full Text] [Related]
19. A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics.
Knight T; Luedtke D; Edwards H; Taub JW; Ge Y
Biochem Pharmacol; 2019 Apr; 162():250-261. PubMed ID: 30668936
[TBL] [Abstract][Full Text] [Related]
20. Potential inhibitors for FKBP51: an
Barge S; Jade D; Ayyamperumal S; Manna P; Borah J; Nanjan CMJ; Nanjan MJ; Talukdar NC
J Biomol Struct Dyn; 2022; 40(24):13799-13811. PubMed ID: 34709133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
